About this event

  • Date and time Tue 26 Jan 2021 from 8:45am to 5:00pm
  • Location Royal Society of Medicine
  • Organised by Endocrinology and Diabetes

*Please note: This event was due to take place on Tuesday 28 April 2020 and has been postponed to Tuesday 26 January 2021. We apologise for any inconvenience this may have caused.*

Join a multidisciplinary faculty of experts at this unique opportunity to learn about new strategies to lower cardiovascular risk, heart failure hospitalisation and mortality in type 2 diabetes patients by using novel anti-diabetes agent. Benefits, rational indications and potential side effects will be discussed.

You will hear about the challenges in managing CVD risk, heart failure and renal disease in diabetes and receive an update on recent clinical trials results, focusing on SGLT2 inhibitors and GLP-1 receptor agonists, highlighting these drugs benefits beyond glycaemic control.

This cross-speciality event will promote collaboration and understanding between general practitioners, cardiologists, nephrologists and endocrinologists working together.

Topics include

  • Update on reducing thrombosis risk in diabetes - participants will learn to rationally use novel anti-thrombosis agents in high risk patients.
  • Discussing the recent clinical trials results on GLP-1 RAs and SGLT2 inhibitors in Type 2 diabetes highlighting these agents benefits in reducing CVD risk, heart failure and kidney disease. Participants will learn how to use these agents rationally and safely promoting collaboration between endocrinologists, primary care, cardiologists and nephrologists.


Standard pricing available until 25 January 2021.


RSM Fellow RSM Associate RSM Retired Fellow RSM Trainee RSM Student
£125.00 £85.00 £85.00 £85.00 £35.00

Non - Member

Consultant / GP AHP / Nurse / Midwife Trainee Student
£180.00 £105.00 £105.00 £50.00

Key speakers

Professor Neil Poulter

Professor of Preventive Cardiovascular Medicine, Imperial College London

Speaker's biography

Professor Neil Poulter qualified at St Mary’s Hospital, London, in 1974, following which he trained in General Medicine. He then spent 5 years in Kenya co-ordinating a collaborative hypertension research programme at the Wellcome Trust Research Laboratories in Nairobi.

On his return to the UK in 1985 he gained an MSc in Epidemiology with distinction at the London School of Hygiene and Tropical Medicine.  Following this he was Co-PI of the WHO Oral Contraceptive case-control Study at University College London Medical School.

In 1997 he was appointed Professor of Preventive Cardiovascular Medicine at Imperial College London, where he is currently co-Director of the International Centre for Circulatory Health and Director of the Imperial Clinical Trials Unit. He is an Honorary Consultant Physician and Epidemiologist at the Peart-Rose (CVD Prevention) Clinic based at Hammersmith Hospital, London, where he is actively involved in the treatment of patients with hypertension and related problems. 

He was President of the British Hypertension Society from 2003-2005 and is the immediate Past-President of the International Society of Hypertension. In 2008, he was elected as one of the Inaugural Senior Investigators of the NIHR and also elected as a fellow of the Academy of Medical Sciences in 2009.  

He has contributed chapters to several major textbooks and published over 460 papers in peer-reviewed medical journals, including co-authoring several sets of national and international guidelines. Professor Poulter is among the top 1% most cited academics in clinical medicine as reported in the Thomson Reuters Highly Cited Researcher 2014 report.

He has played a senior management role in several international trials including the ASCOT, ADVANCE, EXSCEL, DEVOTE and LEADER trials; other research activities include the optimal investigation and management of essential hypertension and dyslipidaemia; the association between birth weight and various cardiovascular risk factors; the cardiovascular effects of exogenous oestrogen and progesterone; the prevention and aetiology of type 2 diabetes and abdominal aortic aneurism; and ethnic differences in cardiovascular disease.

Professor Gerry McKay

Consultant Physician & Clinical Pharmacologist at Glasgow Royal Infirmary

Speaker's biography

Prof McKay contributes to the provision of diabetes care in Glasgow including a specialist interest in diabetic nephropathy, and maintains a commitment to acute medicine. He studied at the University of Glasgow, did early training in the West of Scotland before training in Newcastle in clinical pharmacology which included 4 years on call for the National Poisons Service and secondments to diabetes, the pharmaceutical industry and NICE. He returned to Glasgow via a 3 year spell as a consultant in Monklands District General hospital, Airdrie. He has a variety of research and teaching interests and holds honorary appointments in both the University of Glasgow and University of Strathclyde.

Professor David Wheeler

Professor of Kidney Medicine, UCL, Honorary Consultant Nephrologist, Royal Free Hospital

Speaker's biography

David’s current positions include Professor of Kidney Medicine at University College London, UK and Honorary Consultant Nephrologist at the Royal Free NHS Foundation Trust. He is a Clinician Scientist with an interest in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the design, roll out and monitoring of several large-scale clinical trials. He was a member of the steering committee of the Study of Heart and Renal Protection (SHARP) and the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE). He currently sits on the steering committee of Canaglifozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), acting as UK principle investigator for this study. He is Clinical Lead for Division 2 of the North Thames Clinical Research Network and heads a team of 8 Clinical Trials Nurses/Practitioners at the Centre for Nephrology, Royal Free Hospital in London. He has been involved in Clinical Practice Guideline Development for several organisations, most recently for Kidney Disease, Improving Global Outcomes (KDIGO), of which he is currently co-chair. He is Past President of the UK Renal Association and Chair of the UK Renal Registry. Other responsibilities include Associate Editor of Nephrology, Dialysis Transplantation and member of the Editorial Board of the Journal of the American Society of Nephrology.


View the programme

Registration, tea and coffee
Welcome and introduction

Chair: Dr Abdul Lakhdar, Consultant Endodocrinologist, Barts Health NHS Trust

An update on the management of thrombosis risk in diabetes

Professor Ramzi Ajjan, Consultant in Diabetes, Endocrinology and Thrombosis, Leeds Teaching Hospitals NHS Trust

The deadly duo of heart failure and diabetes: Challenges in management

Dr Raj Amersey, Consultant Cardiologist, Barts Health NHS Trust

Tea and coffee break
The multifactorial benefits of GLP-1 RAs beyond glycaemic control

Professor Gerry McKay, Consultant Physician and Clinical Pharmacologist, Glasgow

GLP-1 Ras - where do they fit in cardiovascular risk management?

Professor Neil Poulter, Professor of Preventative Cardiovascular Medicine, London

Panel discussion

Chair: Dr Ketan Dhatariya, Consultant in Diabetes and Endocrinology and Honorary Professor of Medicine, Norfolk and Norwich University Hospitals NHS Foundation Trust

The renoprotecive effects of SGLT2i

Professor David C Wheeler, Professor of Kidney Medicine, University College London

Heart failure, diabetes and SGLT2i: Time to change practice?

Professor Mark Petrie, Professor of Cardiology, Glasgow

Tea and coffee break
Should cardiologists and nephrologists prescribe SGLT2i?

Professor Miles Fisher, Consultant Physician, Glasgow Royal Infirmary

Diabetes and cardiovascular disease: Time for a multifactorial approach

Professor John E Deanfield, Professor of Cardiology, Director, National Centre for Cardiovascular Prevention and Outcomes, University College London

Panel discussion
Concluding remarks
Close of meeting


Royal Society of Medicine, 1 Wimpole St, Marylebone, London, W1G 0AE, United Kingdom